These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19097323)

  • 1. Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval.
    Lindsley CW
    Curr Top Med Chem; 2008; 8(17):1553. PubMed ID: 19097323
    [No Abstract]   [Full Text] [Related]  

  • 2. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders.
    Antel J; Gregory PC; Nordheim U
    J Med Chem; 2006 Jul; 49(14):4008-16. PubMed ID: 16821760
    [No Abstract]   [Full Text] [Related]  

  • 3. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.
    Lee HK; Choi EB; Pak CS
    Curr Top Med Chem; 2009; 9(6):482-503. PubMed ID: 19689362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
    Wright KL; Robertson DA; Moyer MP; Ward SG
    Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
    [No Abstract]   [Full Text] [Related]  

  • 5. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
    Giraldo J
    Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA approval of obesity drugs: a difference in risk-benefit perceptions.
    Morrato EH; Allison DB
    JAMA; 2012 Sep; 308(11):1097-8. PubMed ID: 22990266
    [No Abstract]   [Full Text] [Related]  

  • 7. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
    Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-obesity drugs: to be or not to be?
    Dvorak RV; Sharma AM; Astrup A
    Obes Rev; 2010 Dec; 11(12):833-4. PubMed ID: 21054758
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison table: some FDA-approved drugs for weight management.
    Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464
    [No Abstract]   [Full Text] [Related]  

  • 11. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug management of obesity--efficacy versus safety.
    Astrup A
    N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 17. Cannabinoid receptor antagonists and obesity.
    Black SC
    Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.
    Aggarwal R; Vaduganathan M; Chiu N; Bhatt DL
    Prog Cardiovasc Dis; 2021; 68():97-98. PubMed ID: 34560122
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.